Severe pancytopenia caused by trifluridine/tipiracil in patients with metastatic colorectal cancer and an impaired renal function: A case report | Zendy

Shibutani Masatsune | Zendy; Okazaki Yuki | Zendy; Kashiwagi Shinichiro | Zendy; Nagahara Hisashi | Zendy; Fukuoka Tatsunari | Zendy; Iseki Yasuhito | Zendy; Maeda Kiyoshi | Zendy; Hirakawa Kosei | Zendy; Ohira Masaichi | Zendy

Open Access

Severe pancytopenia caused by trifluridine/tipiracil in patients with metastatic colorectal cancer and an impaired renal function: A case report

Author(s) -

Shibutani Masatsune,

Okazaki Yuki,

Kashiwagi Shinichiro,

Nagahara Hisashi,

Fukuoka Tatsunari,

Iseki Yasuhito,

Maeda Kiyoshi,

Hirakawa Kosei,

Ohira Masaichi

Publication year - 2022

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.5544

Subject(s) - medicine , pancytopenia , colorectal cancer , incidence (geometry) , adverse effect , toxicity , renal function , gastroenterology , oncology , cancer , bone marrow , physics , optics

Although the incidence of hematological toxicity due to Trifluridine/tipiracil (FTD/TPI) treatment is high, the incidence of severe adverse events has been reported to be relatively low. However, it should be noted that patients with renal impairment are prone to severe hematological adverse events.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research